Raymond James analyst Mitch Ingles upgrades Carvana (NYSE:CVNA) from Underperform to Market Perform.
Stifel Maintains Buy Rating for Revolution Medicines: Here’s What You Need To Know
Stifel has decided to maintain its Buy rating of Revolution Medicines (NASDAQ:RVMD) and raise its price target from…